U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07811089) titled 'Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OMS1620' on Aug. 10.
Brief Summary: The goal of this study is to explore the safety, drug concentrations and effects on adrenal gland hormones after a single dose or multiple doses of OMS1620 in healthy participants. In addition, the effect of food on drug concentrations will also be tested.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Congenital Adrenal Hyperplasia (CAH)
Intervention:
DRUG: OMS1620
OMS1620 is an oral small molecule antagonist of the melanocortin 2 receptor (MC2R), the receptor for adrenocorticotrophic hormone (ACTH)
DRUG...